Ann: 2024 EGM Notice of Meeting, page-24

Respectfully, while OB may have your support, the objective reality, reflected in the share price decline of over 90% since his appointment, indicates a lack of widespread confidence. His background in stockbroking and finance, with limited non-executive biotech experience, raises concerns about his suitability for the role. Despite being in the position since December 2021, he has not proactively implemented or successfully executed a comprehensive global strategy, particularly concerning the crucial EU market and the IVDR reforms, nor US. The delayed response to regulatory shifts and the dismissive tone towards the 249D claims lack maturity and accountability. The pre-population of the proxy appears dubious and unethical. After more than two years, shareholders deserve new leadership. The requisitioning shareholders' letter suggests change is essential to prevent further value destruction and move the company forward. Given the prolonged poor performance since OB's appointment in December 2021 on a "short-term" basis, a dignified resignation might be a more appropriate response than further depletion of shareholder equity and time.